News & Insights

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company’s Board of Directors approved “inducement” grants to 20 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 44,350 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and v

HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--The five-patient FDA Early Feasibility Study of BiVACOR Total Artificial Heart successfully bridges all to a donor heart transplant-EFS expanded to 15

PASADENA, Calif.--(BUSINESS WIRE)--Holoclara initiates Phase 1 clinical trial evaluating worm-derived therapeutic HC002 in healthy adults

PASADENA, Calif.--(BUSINESS WIRE)--Holoclara selects eosinophilic esophagitis as its lead indication for HC002, a first-in-class worm-derived therapy

LOS ANGELES--(BUSINESS WIRE)--For the press release dated December 16, 2024, add caption: Left to Right: Joseph Miller, MD, MS, Director of Interventional Radiology, and Phoenix Hunt, VR Technologist. (Photo: Business Wire) The release reads: CHILDREN’S HOSPITAL LOS ANGELES USES VIRTUAL REALITY TO TRANSFORM MINIMALLY INVASIVE PROCEDURES FOR PATIENTS If your heart rate increases each time you hear the word “injection,” you’re not alone. Every 1 in 4 adults has a fear of needles—a fear that most

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ United States proudly announces its VITOM® eagle exoscope with ARTip CRUISE® motorized holding system has received an Innovative Technology designation from Vizient, Inc., the largest provider-driven healthcare performance improvement company in the country. KARL STORZ exhibited the VITOM eagle and ARTip CRUISE at this year’s Vizient Innovative Technology Exchange in Las Vegas. Each year, healthcare experts serving on Vizient provider-led councils

LOS ANGELES--(BUSINESS WIRE)--Children’s Hospital Los Angeles team finds biomarker combination that could predict liver fibrosis early enough to reverse liver damage.

LONG BEACH, Calif.--(BUSINESS WIRE)---- $RKLB--Rocket Lab has successfully delivered its second Pioneer spacecraft to Vandenberg Space Force Base and completed production of a third for Varda.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PT in San Francisco, CA. A live and archived webcast for these events, where applicable, will be available in

FOSTER CITY, Calif. & LOS ANGELES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Terray’s tNova platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug discovery engine. The company’s iterative approach applies AI-empowered methods to an

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company” or “Adagio”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that founder Olav Bergheim departed as Chief Executive Officer (“CEO”) and Chairperson of the Board of Directors of the Company, effective December 13, 2024. Concurrently, the Company announced the appointment of Todd Usen, as Chief Executive Officer and Director of the Company

CALABASAS, Calif.--(BUSINESS WIRE)--Nationwide Medical, a national provider of home medical equipment, announces growth partnership with Heritage Group.

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc., today announced it will be presenting new data highlighting MammaPrint® and BluePrint® utility in guiding treatment decisions for patients with early-stage breast cancer. The findings will be presented in two spotlight presentations and two posters at the San Antonio Breast Cancer Symposium 2024 (SABCS), on Wednesday, December 11th and Thursday, December 12th. One poster spotlight, titled “Association of MammaPrint® with gene expressi

LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company is restarting a process to seek marketing approval of aldoxorubicin under the provisions of the FDA’s Section 505(b)(2). The 505(b)(2) pathway is designed for a new drug composition whose active ingredient is the same active ingredient as a drug previously approved b

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc., today announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint®’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024 (SABCS), on Wednesday, December 11th. The study, presented by Adam Brufsky, MD, PhD, Professor and Associate Chief of Hematology and Oncology at UPMC

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases. The data were presented today, December 11, 2024, at the 8th Complement-Based Drug Development Summit being held in Boston. “Dysregulated activation of the complement sy

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, ImmunityBio expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions.

LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, whose Los Angeles comprehensive cancer center is ranked among the nation’s top 5 cancer centers by U.S. News & World Report, presented new study results on treatment options, side effect prevention and risk prediction for blood cancer patients at this year’s ASH conference in San Diego, California, held Dec. 7 to 10. Scientists

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ United States, a leader in surgical innovation and operating room (OR) integration, announces the US launch of Pathway.AI, a new tool powered by the Artisight Smart Hospital Platform. By detecting and responding to status changes in the OR, Pathway.AI may help reduce turnover times and eliminate many manual tasks, thereby enhancing OR efficiency and increasing data accuracy. “Artisight’s expertise in healthcare AI is the perfect complement to KARL

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- #MoranEyeCenter--ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a research partnership with the John A. Moran Eye Center at the University of Utah (Moran Eye Center), home to the renowned Alan S. Crandall Center for Glaucoma Innovation (Crandall Center). The collaboration will explore aqueous outflow dynamics of ViaLase’s novel ViaLase laser procedure, utilizing Mo

LOS ANGELES--(BUSINESS WIRE)--City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, whose Los Angeles comprehensive cancer center is ranked among the nation’s top five cancer centers by U.S. News & World Report, reported on promising early results from a phase 1b/2 clinical trial using epcoritamab, a new bispecific T cell engager, for patients with relapsed or refractory CLL. Alexey Danilov, M.D., Ph.D., City of Hope’s Marianne

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas (NHL) including follicular lymphoma (FL) or marginal zone lymphoma (MZL). The analysis demonstrated that after a median follow-up of more than five years, patients treated with Yescarta continued to experience durable response and long-

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabtagene autoleucel) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The data presented include an oral presentation

LOS ANGELES--(BUSINESS WIRE)--City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, announced today that its CEO, Robert Stone, has been named to Modern Healthcare’s prestigious list of the 100 Most Influential People in Health Care. This distinction, one of the highest honors in health care, acknowledges transformative leaders who are shap

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today announced that it has filed its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the SetPoint System, a potential first-of-its-kind neuroimmune modulation device for adults living with moderate-to-severe rheumatoid arthritis (RA) who are incomplete responders or are intolerant to biologic or targeted sy

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were presented at 66th American Society of Hematology (ASH) Annual Meeting & Exposition. The data include findings from the largest real-world analysis of patients who received Yescarta as second-line trea

LOS ANGELES--(BUSINESS WIRE)--A national leader in pediatric gene therapy, CHLA has treated more patients with the sight-saving Luxturna than any other center in the country.

MARSEILLE, France & DIAMOND BAR, Calif.--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), together with the Institute for Follicular Lymphoma (IFLI) today announced that they have entered into an agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in follicular lymphoma (FL). Innate’s ongoing Phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplas

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to a November new hire, as required under Nasdaq Listing Rule 5635(c)(4).

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients. City of Hope Cancer Center is the first of several planned new centers to be added in the coming weeks to support the Company

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company’s second investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is the first RNAi-based therapy to directly target a gene expressed in adipose tissue and highlights Arrowhead’s leadership in the delivery of siRNA to multipl

EL SEGUNDO, Calif. & KNOXVILLE, Tenn.--(BUSINESS WIRE)--Radiology Partners (RP), the leading radiology practice in the U.S. through its owned and affiliated practices, and RADPAIR, a leader in generative AI-driven radiology solutions, today announced a strategic partnership to advance radiology innovation and address critical capacity challenges. The collaboration focuses on the co-development of advanced AI driven reporting tools designed to enhance accuracy and reimagine radiologist workflow.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 36th Annual Healthcare Conference – December 3-5, 2024 Type: Fireside Chat Presentation Date/Time: December 3, 2024, 1:30 p.m. EST 7th Annual Evercore ISI HealthCONx Conference – December 3-5, 2024 Type: Fireside Chat Presentation Date/Time: December 4, 2024, 2:10 p.m. EST The APA/JPS/CAP/IAP 2024 Joint Meeting – De

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 3:50 p.m. EST. A li

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT Location: New York City 7th Annual Evercore HealthCONx Conference Date: Wedn

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. “Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiM™ technology. We have the potential to impact the lives of millions

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 8:30 a.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide arr

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT). Upon closing, Arrowhead will receive $825 million, consisting of $500 million cash and $325 million as an equity investment priced at a 35% premium. Arrowhead also receives $250 million to be paid in equal installments over five years and is eligible to receive an additional $300 million in near-term payments,

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc., announced today that new data on its early-stage breast cancer genomic tests and their ability to inform treatment selection decisions will be presented at the San Antonio Breast Cancer Symposium 2024 (SABCS), taking place in San Antonio, TX, December 10th – 13th, 2024. The presented data highlights Agendia’s continued focus on expanding clinical utility of the tests and optimizing breast cancer management throughout the patient’s tre

LOS ANGELES--(BUSINESS WIRE)-- #innovator--MedTech Innovator (MTI), the world’s largest accelerator of medical technology companies, today announced that LATTICE Medical won the 2024 Mid-Stage Grand Prize competition, and Flow Medical won the 2024 Value Award during the MedTech Strategist Innovation Summit in San Diego. LATTICE Medical received $200,000 in non-dilutive cash proceeds as the Mid-Stage Grand Prize winner, and Flow Medical received $25,000 in non-dilutive cash as the Value Award winner. During

LOS ANGELES--(BUSINESS WIRE)-- #ActRII--Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer diseases, is pleased to announce a clinical collaboration with Eli Lilly and Company (Lilly), a global leader in cardiometabolic health, including diabetes and obesity, to accelerate the development of LAE102, a novel ActRIIA mAb as a novel treatment for obesity. Accelerating innovative treatments like this hopefully can make a meaningful impact on

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated a clinical trial of alisertib with endocrine therapy in patients with HR+ HER2-negative metastatic breast cancer.

HAWTHORNE, Calif.--(BUSINESS WIRE)--OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced that its Optoelectronics and Manufacturing division has received an order for approximately $11 million to provide critical electronic sub-assemblies for a leading-edge healthcare original equipment manufacturer (OEM), known for innovative and specialized medical solutions. OSI Systems’ Chairman and Chief Executive Officer, Deepak Chopra, stated, “We are pleased with this award

IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis, Inc., a clinical-stage biotech developing novel, multi-active biologics for age and disease-related immune dysregulation, is proud to announce the successful completion of its Phase 1/2a clinical trial. The clinical study investigated the safety, tolerability, and preliminary efficacy of Immunis’ investigational therapy, IMM01-STEM, in reversing muscle atrophy in elderly individuals with knee osteoarthritis. "Completing this clinical trial is a signific

IRVINE, Calif.--(BUSINESS WIRE)--Hyperice, the leading global high-performance wellness brand, today announced its Black Friday deals, which include the lowest prices of the year starting on November 21 and continuing through December 8, 2024. Whether you are shopping for the athlete who has everything, a busy parent, a world traveler, or even treating yourself, Hyperice’s suite of award-winning wellness technology has you covered this holiday season. IMAGES: CLICK HERE This year’s extensive Bl

LANCASTER, Calif.--(BUSINESS WIRE)--CEO of Simulations Plus, Shawn O’Connor, will participate in a panel discussion at the virtual BTIG Digital Health Forum on Monday, November 25, 2024.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of November 2024, 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (NMIBC CIS) have been treated with ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with BCG, achieving a 71% complete response (CR) rate. In these responders, the range

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today announced late-breaking data from the RESET-RA study presented at the American College of Rheumatology (ACR) Convergence 2024, the largest global gathering of rheumatologists. New clinical trial results support the SetPoint System's potential as a first-of-its-kind neuroimmune modulation treatment for adults living with moderate-to-severe rh

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no FDA approved treatments. Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to a